Breaking News Instant updates and real-time market news.

EPZM

Epizyme

18:47
04/09/18
04/09
18:47
04/09/18
18:47

Epizyme publishes Phase 1 Tazemetostat study in The Lancet Oncology

Epizym announced its first-in-human data on the effects of EZH2 inhibition in patients with advanced solid tumors and B-cell non-Hodgkin lymphoma was published in the peer-reviewed The Lancet Oncology. The objectives of the Phase 1 dose-escalation portion of the study were to evaluate the safety and tolerability of orally dosed tazemetostat, a first-in-class selective inhibitor of EZH2. The study established the recommended dose for the Phase 2 expansion study and demonstrated favorable safety findings and anti-tumor activity. The open-label Phase 1 study was designed to evaluate the maximally tolerated dose and supported defining the recommended Phase 2 dose of tazemetostat. Tazemetostat was dosed twice daily as a single agent in patients with relapsed or refractory B-cell NHL or with advanced solid tumors including molecularly defined INI1- or SMARCA4-negative tumors. Additional study objectives were to evaluate the adverse events, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of the agent. The results of the safety, PK and PD analyses helped determine the RP2D of 800 mg twice daily. The most common treatment-related adverse events, regardless of attribution, were grade 1 or 2 asthenia, anorexia, anemia, muscle spasms, nausea and vomiting. One single dose-limiting toxicity of grade 4 thrombocytopenia was identified at the highest dose of 1600 mg, but no other grade 3 or 4 toxicities were observed at a frequency greater than 5%.

  • 25

    Apr

EPZM Epizyme

03/14/18
RHCO
03/14/18
NO CHANGE
Target $27
RHCO
Buy
Epizyme price target raised to $27 from $21 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Epizyme to $27, saying the company's Q4 earnings call reiterated expectations of on-track data flow in epithelioid sarcoma registrations / NDA filing later this year, the combo data for DLBCL, and the follicular lymphoma data and registration path in the second half of 2018. Lawson keeps his Buy rating and attributes his price target revision to the treatment's higher probability of success.
02/01/18
02/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Roth Capital. 2. Take-Two (TTWO) initiated with an Overweight at Morgan Stanley. 3. AMERI Holdings (AMRH) initiated with an Outperform at Northland. 4. Simply Good Foods (SMPl) initiated with a Buy at SunTrust. 5. Zynerba (ZYNE) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/01/18
ROTH
02/01/18
INITIATION
Target $24
ROTH
Buy
Epizyme initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Epizyme with a Buy rating and $24 price target as he believes its lead agent tazemetostat, an inhibitor of the histone methyltrasferase EZH2, has laid out a sufficiently wide clinical footprint, and is sufficiently close to an NDA in several indications, that even his conservative approach of ranking its clinical programs shows that the company still remains undervalued.
01/24/18
JEFF
01/24/18
INITIATION
Target $25
JEFF
Buy
Epizyme assumed with a Buy at Jefferies
Jefferies analyst Michael Yee assumed coverage of Epizyme with a Buy rating and raised his price target for the shares to $25 from $23. The company represents an "attractive smid-cap cancer play" with lead drug tazemetostat having activity across a broad range of tumors, Yee tells investors in a research note.

TODAY'S FREE FLY STORIES

DXC

DXC Technology

$102.23

-0.8 (-0.78%)

14:15
04/25/18
04/25
14:15
04/25/18
14:15
Options
DXC Technology put volume heavy and directionally bearish »

Bearish flow noted in DXC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

14:14
04/25/18
04/25
14:14
04/25/18
14:14
Hot Stocks
Maryland announces $35M settlement with Volkswagen over defeat devices »

Maryland Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$18.82

-0.66 (-3.39%)

14:10
04/25/18
04/25
14:10
04/25/18
14:10
Hot Stocks
Acadia falls after FDA said to open re-examination of Parkinson's drug »

Shares of Acadia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$11.02

0.07 (0.64%)

, GM

General Motors

$37.80

-0.12 (-0.32%)

14:07
04/25/18
04/25
14:07
04/25/18
14:07
Earnings
On The Fly: What to watch in auto space earnings reports »

Ford (F) and General…

F

Ford

$11.02

0.07 (0.64%)

GM

General Motors

$37.80

-0.12 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 01

    May

  • 20

    Jun

TWTR

Twitter

$29.24

-1.24 (-4.07%)

14:05
04/25/18
04/25
14:05
04/25/18
14:05
Upgrade
Twitter rating change  »

Twitter upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 27

    Jul

TMUS

T-Mobile

$63.95

1.37 (2.19%)

14:05
04/25/18
04/25
14:05
04/25/18
14:05
Options
T Mobile call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPKE

Spark Energy

$11.78

0.025 (0.21%)

14:04
04/25/18
04/25
14:04
04/25/18
14:04
Periodicals
Breaking Periodicals news story on Spark Energy »

Spark Energy said to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 10

    May

ACAD

Acadia

$19.95

0.47 (2.41%)

14:00
04/25/18
04/25
14:00
04/25/18
14:00
Periodicals
FDA head says will 'take another look' at Acadia's Nuplazid, CNN reports »

In response to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$304.83

-2.41 (-0.78%)

13:58
04/25/18
04/25
13:58
04/25/18
13:58
Conference/Events
Netflix management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

MSFT

Microsoft

$92.23

-0.85 (-0.91%)

13:55
04/25/18
04/25
13:55
04/25/18
13:55
Conference/Events
House Appropriations Committee to hold a hearing »

The Labor, Health &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

ZOOM

Zoom Technologies

13:55
04/25/18
04/25
13:55
04/25/18
13:55
Conference/Events
Zoom Technologies participates in a conference call with RBC Capital »

RBC Capital Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JD

JD.com

$35.84

-0.03 (-0.08%)

13:50
04/25/18
04/25
13:50
04/25/18
13:50
Options
Volatility play in JD as January puts trade in large blocks Wednesday »

Volatility play in JD as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
04/25/18
04/25
13:50
04/25/18
13:50
General news
Treasury Curve Action: steepeners resumed »

Treasury Curve Action:…

AMD

AMD

$9.69

-0.4 (-3.96%)

13:40
04/25/18
04/25
13:40
04/25/18
13:40
Options
Aggresive buyer lays out $2.2M for deep in the money Advanced Micro puts »

Aggresive buyer lays out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

AAPL

Apple

$164.70

1.83 (1.12%)

13:40
04/25/18
04/25
13:40
04/25/18
13:40
Conference/Events
President Trump to meet with Apple CEO Cook »

The meeting between…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

WELL

Welltower

$49.86

-1.16 (-2.27%)

, QCP

Quality Care Properties

$21.35

0.55 (2.64%)

13:37
04/25/18
04/25
13:37
04/25/18
13:37
Periodicals
Promedica, Welltower offering $2B to aquire Quality Care Properties, Reuters says »

Promedica and Welltower…

WELL

Welltower

$49.86

-1.16 (-2.27%)

QCP

Quality Care Properties

$21.35

0.55 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

  • 04

    May

EBAY

eBay

$40.63

-0.55 (-1.34%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Technical Analysis
Technical Earnings Preview: eBay in uptrend ahead of earnings »

The shares have been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LC

LendingClub

$2.78

-0.485 (-14.85%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Hot Stocks
LendingClub calls charges in FTC complaint 'legally and factually unwarranted' »

Following an inquiry that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

LC

LendingClub

$2.78

-0.485 (-14.85%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Hot Stocks
Breaking Hot Stocks news story on LendingClub »

LendingClub calls charges…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

FB

Facebook

$160.15

0.49 (0.31%)

, GOOG

Alphabet

$1,021.04

1.58 (0.15%)

13:35
04/25/18
04/25
13:35
04/25/18
13:35
Periodicals
Facebook declines to testify at U.S. House hearing on social media, Reuters says »

A Facebook (FB) spokesman…

FB

Facebook

$160.15

0.49 (0.31%)

GOOG

Alphabet

$1,021.04

1.58 (0.15%)

GOOGL

Alphabet Class A

$1,023.95

0.97 (0.09%)

TWTR

Twitter

$28.98

-1.5 (-4.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 30

    May

  • 27

    Jul

HOG

Harley-Davidson

$41.88

-0.13 (-0.31%)

13:30
04/25/18
04/25
13:30
04/25/18
13:30
Options
Hefty spread opened in Harley Davidson options »

Hefty spread opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

TWTR

Twitter

$28.97

-1.51 (-4.95%)

13:29
04/25/18
04/25
13:29
04/25/18
13:29
Recommendations
Twitter analyst commentary  »

Twitter outlook looks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 27

    Jul

XOM

Exxon Mobil

$78.56

0.21 (0.27%)

13:29
04/25/18
04/25
13:29
04/25/18
13:29
Hot Stocks
Exxon Mobil boosts Q2 dividend to 82c from 77c »

Exxon Mobil's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FB

Facebook

$160.04

0.38 (0.24%)

13:25
04/25/18
04/25
13:25
04/25/18
13:25
Technical Analysis
Technical Earnings Preview: Facebook in an active bearish pattern before news »

There is a bearish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MGM

MGM Resorts

$35.36

-0.16 (-0.45%)

13:25
04/25/18
04/25
13:25
04/25/18
13:25
Options
MGM Resorts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.